Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
- Previous Close
48.80 - Open
49.12 - Bid 49.08 x --
- Ask 49.12 x --
- Day's Range
48.94 - 49.42 - 52 Week Range
40.62 - 53.40 - Volume
273,233 - Avg. Volume
215,316 - Market Cap (intraday)
10.133B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
26.40 - EPS (TTM)
1.86 - Earnings Date May 9, 2024
- Forward Dividend & Yield 1.26 (2.57%)
- Ex-Dividend Date May 20, 2024
- 1y Target Est
52.00
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
www.recordati.com4,455
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: REC.MI
Performance Overview: REC.MI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REC.MI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REC.MI
Valuation Measures
Market Cap
10.13B
Enterprise Value
11.72B
Trailing P/E
26.38
Forward P/E
17.99
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.93
Price/Book (mrq)
6.01
Enterprise Value/Revenue
5.63
Enterprise Value/EBITDA
16.54
Financial Highlights
Profitability and Income Statement
Profit Margin
18.69%
Return on Assets (ttm)
9.54%
Return on Equity (ttm)
24.08%
Revenue (ttm)
2.08B
Net Income Avi to Common (ttm)
389.21M
Diluted EPS (ttm)
1.86
Balance Sheet and Cash Flow
Total Cash (mrq)
221.81M
Total Debt/Equity (mrq)
108.45%
Levered Free Cash Flow (ttm)
32.58M
Research Analysis: REC.MI
Company Insights: REC.MI
REC.MI does not have Company Insights